Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

10.92USD
16 Feb 2018
Change (% chg)

$0.07 (+0.65%)
Prev Close
$10.85
Open
$10.80
Day's High
$11.25
Day's Low
$10.80
Volume
239,228
Avg. Vol
295,864
52-wk High
$27.78
52-wk Low
$9.83

Select another date:

Tue, Jan 30 2018

BRIEF-Achaogen Announces Upgraded Status For Plazomicin Fill Manufacturer

* SAYS ‍FDA CLASSIFIED OUTCOME OF ITS Q4 2017 REINSPECTION OF PFIZER'S MCPHERSON FACILITY AS VOLUNTARY ACTION INDICATED​ Source text for Eikon: Further company coverage:

BRIEF-Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape

* ACHAOGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST CLINICAL TRIAL OF ORALLY-ADMINISTERED ANTIBACTERIAL CANDIDATE C-SCAPE

BRIEF-Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin

* ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS

BRIEF-Achaogen Appoints Blake Wise Chief Executive Officer

* ACHAOGEN INC - KENNETH HILLAN TO BECOME PRESIDENT, RESEARCH AND DEVELOPMENT

BRIEF-Achaogen reports Q3 loss per share $0.85

* Achaogen reports third quarter 2017 financial results and provides corporate update

BRIEF-Achaogen submits Plazomicin new drug application to FDA

* Achaogen submits Plazomicin new drug application (NDA) to the U.S. FDA for treatment of complicated urinary tract infections and bloodstream infections

BRIEF-Achaogen awarded up to $18 million contract by BARDA

* Achaogen awarded up to $18 million contract by BARDA to support development of orally-administered antibacterial candidate C-Scape

Select another date: